Clinical Trials Logo

Clinical Trial Summary

This early phase I study gathers information about how the body responds to COVID-19 vaccine during cancer treatment compared to healthy individuals. The information gained may help determine how effective currently available COVID-19 vaccines are in cancer patients receiving chemotherapy and learn more regarding how long an immune response will last compared to healthy individuals.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the antibody response to COVID-19 vaccine after vaccination. II. To assess the adverse events of COVID-19 vaccines in cancer patients. III. To determine the incidence and severity of COVID-19 infection after the vaccination. OUTLINE: Patients undergo blood sample collection at baseline (prior to first vaccination), prior to second vaccination, 1, 6, and 12 months after the last vaccination. Patients who receive the types of COVID-19 vaccines that do not require the second injection omit the blood sample collection prior to the second vaccination. For patients who have already received COVID-19 vaccines, medical records are reviewed retrospectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04865133
Study type Observational
Source Mayo Clinic
Contact
Status Recruiting
Phase
Start date March 31, 2021
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04379518 - Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients Phase 1/Phase 2
Not yet recruiting NCT04871542 - Side Effects From Immune Checkpoint Inhibitor Therapy in Patients With Solid Tumors
Recruiting NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Recruiting NCT04602026 - Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial N/A
Recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Active, not recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Recruiting NCT04089358 - Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study Phase 3
Recruiting NCT02402244 - Project: Every Child for Younger Patients With Cancer
Recruiting NCT01989585 - Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1/Phase 2
Recruiting NCT04532372 - Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Phase 1/Phase 2
Recruiting NCT04630431 - Understanding the Challenges, Behavioral Patterns, and Preferences Towards Participation in Clinical Trials in Minority Patient Populations
Recruiting NCT02515383 - Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)
Recruiting NCT04436835 - Psychotherapy (Accelerated Resolution Therapy) for Cancer Related Trauma and Distress N/A